Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
Clearmind Medicine Inc. has reached a significant clinical milestone by successfully dosing 20 participants in its ongoing multinational Phase I/IIa trial of CMND-100 (MEAI) for treating moderate to severe Alcohol Use Disorder (AUD). The trial, which is FDA-approved and taking place across multiple leading institutions including Yale and Johns Hopk…